Novartis AG vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.69. The key difference: Novartis AG pays a 3.17% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Novartis AG is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| NVS | VNQI | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | — |
52-Week High | $168.62 | $50.76 |
52-Week Low | $113.50 | $43.26 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →